NLSUI OPAC header image

Excessive pricing in pharmaceutical market : cci should intervene or not? (Record no. 217467)

MARC details
000 -LEADER
fixed length control field 02190nam a2200145Ia 4500
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20260209120143.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 260209s9999||||xx |||||||||||||| ||und||
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Parnika Agnihotri
245 #0 - TITLE STATEMENT
Title Excessive pricing in pharmaceutical market : cci should intervene or not?
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Place of publication, distribution, etc. BangaloreBangalore
Name of publisher, distributor, etc. NLSIU
Date of publication, distribution, etc. 2020
300 ## - PHYSICAL DESCRIPTION
Extent 39 p. ; 25 cm.
505 ## - FORMATTED CONTENTS NOTE
Formatted contents note TABLE OF CONTENT INTRODUCTION; WHAT IS EXCESSIVE PRICING? ; A. What is wrong with High prices? ; B. Jurisprudence of Excessive pricing ; SECTION II ; EXCESSIVE PRICING IN PHARMACEUTICAL AT THE LEFT SIDE OF ATLANTIC (EU and UK) ; A. European Union ; A.1 United Brand Company and United Brand Continental BVv. Commission of European Communities ; A.2 Autortiesibu un komunicganas konsultaciju agentura / Latvijas Autoru apvieniba v. Konkurences padome ; A.3 Aspen Pharma: Investigation by DG Competition ; A.4 Denmark- CD Pharma Case ; A.5 Germany- Valium Case ; B. UNITED KINGDOM ; B. 1 Napp Pharmaceuticals Holding v. Director General of Fair Trading ; B. 2 Pfizer/ Flynn v. CMA case ; C. Analysing intervention of EU and UK Competition Authorities in Excessive Pricing; SECTION III ; EXCESSIVE PRICING IN PHARMACEUTICAL AT THE RIGHT SIDE OF ATLANTIC (U.S.) ; A. Conventional Approach Towards Excessive pricing ; B. Brief Overview About Pharmaceutical Market in U.S ; C. Approach OF US after Daraprim Case ; C. 1 Daraprim Case ; C 2 Mylan’s EpiPens Case ; SECTION IV ; REGULATING PHARMACEUTICAL PRICES IN INDIA ; A. Drug Price Control Order, 2013 ; B. Ceiling Price Mechanism ; C. Has India’s Drug Price control mechanism destroyed Competition? ; SECTION V ; CCI SHOULD INTERVENE OR NOT ; A. CCI’s experience against excessive pricing in pharmaceuticals ; A.1 In re: Vivek Sharma v. Becton Dickinson India Pvt. Ltd. &Max Hospital; A.2 Biocon & anr. v. F. Hoffmann- La- Roche Ag & Ors; B. Intervention v. Non- Intervention ; C. PRICES ARE REGULATED: STILL NEED INVETERVENTION OF CCI ; SECTION IV ; CONCLUSION ; REFERENCES ; 1. STATUTES ; 2. CASES ; 3. REPORTS ; 4. BOOKS ; 5. ARTICLES .
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Prof. Rahul Singh - GuideProf. Rahul Singh - Guide
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://dans.nls.ac.in/handle/123456789/416">https://dans.nls.ac.in/handle/123456789/416</a>
Holdings
Withdrawn status Lost status Damaged status Not for loan Home library Current library Date acquired Total Checkouts Barcode Date last seen Price effective from Koha item type
        . . 09.02.2026   LLM832 09.02.2026 09.02.2026 Dissertation